Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lubiprostone is a prescription chloride channel activator used to treat selected constipation disorders. Current capsules contain 8 mcg or 24 mcg. U.S. labeling includes chronic idiopathic constipation in adults, opioid-induced constipation in adults with chronic non-cancer pain, and irritable bowel syndrome with constipation in women age 18 and older.
read more about lubiprostone ...Lubiprostone activates chloride channels in the intestinal lining, increasing chloride-rich fluid secretion into the intestine. This increases intestinal fluid and promotes movement of stool through the digestive tract. Its action occurs mainly within the gastrointestinal tract.
Lubiprostone is used for chronic idiopathic constipation in adults and opioid-induced constipation in adults with chronic non-cancer pain. It also treats irritable bowel syndrome with constipation in women age 18 and older. Its activity for opioid-induced constipation in patients receiving methadone or other diphenylheptane opioids has not been established. Known or suspected mechanical gastrointestinal obstruction is a contraindication.
Chronic idiopathic constipation and opioid-induced constipation use 24 mcg by mouth twice daily. Irritable bowel syndrome with constipation uses 8 mcg twice daily. Capsules are taken with food and water and swallowed whole. Moderate or severe hepatic impairment can require lower doses depending on the indication.
Serious concerns include severe diarrhea, fainting, low blood pressure, and difficulty breathing. Nausea, abdominal pain, headache, and abdominal bloating can also occur. Patients with severe diarrhea do not take lubiprostone, and those who develop fainting, breathing difficulty, or persistent diarrhea require medical evaluation.
Lubiprostone treats chronic idiopathic constipation, selected opioid-induced constipation, and irritable bowel syndrome with constipation in adult women.
The recommended dose is 24 mcg twice daily with food and water.
The recommended dose for women age 18 and older is 8 mcg twice daily.
Yes. Difficulty breathing has been reported during treatment, including after early doses.
DailyMed - LUBIPROSTONE capsule, gelatin coated. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f06d76d2-028a-629f-e053-2995a90a80f5. Date Accessed October 13, 2026.
Lubiprostone. FDA Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/7662KG2R6K. Date Accessed October 13, 2026.
Lubiprostone. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a607034.html. Date Accessed October 13, 2026.
Lubiprostone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lubiprostone. Date Accessed October 13, 2026.
Laxatives. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK537246/. Date Accessed October 13, 2026.